Imvionix has acquired exclusive commercial rights to brolucizumab-dbll (Beovu) in the United States and Canada from Novartis. According to a company press release, this acquisition marks the official commercial launch of Imvionix.

Beovu is approved in both the United States and Canada for the treatment of neovascular age-related macular degeneration and diabetic macular edema. Under the terms of the agreement, Imvionix will become the marketing authorization holder for Beovu in the United States and Canada. Financial terms of the transaction were not disclosed.

Imvionix was founded in 2025 by the former executive management team of Alimera Sciences in collaboration with Caligan Partners LP and Velan Capital. The founding team brings a combined 60 years of expertise in ophthalmology, the company said in the press release.